Blum, Joanne L. http://orcid.org/0000-0002-7951-6645
DiCristo, Caroline
Gordon, David
Karuturi, Meghan S.
Oubre, David
Jepsen, Erin
Cuevas, Juan
Lakhanpal, Shailendra
Montelongo, Monica Z.
Zhang, Zhe
Cappelleri, Joseph C.
Wang, Yao
Tripathy, Debu
Funding for this research was provided by:
Pfizer
Article History
Received: 24 June 2023
Accepted: 25 September 2023
First Online: 30 October 2023
Declarations
:
: Joanne L. Blum has received consulting fees from Puma Biotechnology, Athenex Inc, OncLive, Biotheranostics Inc, AstraZeneca, Immunomedics Inc, Research to Practice, Sanofi, Pfizer Inc and Tempus and has participated in Speaker’s Bureaus for Pfizer Inc and Tempus. David Gordon, David Oubre, Juan Cuevas, and Shailendra Lakhanpal have no potential conflicts of interest to disclose. Meghan S. Karuturi has received consulting fees from Pfizer Inc. Erin Jepsen is an employee of Novant Health Cancer Institute. Caroline DiCristo, Zhe Zhang, Joseph Cappelleri, and Yao Wang are employees of Pfizer Inc and may hold stock or stock options. Debu Tripathy has received consulting fees from AstraZeneca, GlaxoSmithKline, OncoPep, AMBRX, Menarini-Stemline, Personalis, Puma Biotechnology, Roche and Sermonix and has performed contracted research for Pfizer Inc and Novartis.
: All patients provided written informed consent.
: The study was conducted in accordance with legal and regulatory requirements. Prospective approvals of the study protocol and related documents were obtained from institutional review boards/independent ethics committees for each site.